Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study.

J Neurooncol · 2026 · PMC12953324 · PMID 41770393

Europe PMC DOI

hedged sentences

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

showed a trendP = 0.073so close (0.05 < p ≤ 0.1)

However, achieving a CR before maintenance therapy showed a trend toward prolonged PFS ( P = 0.073).

also in 53,322 other papers

highly significantno p-value reported

This difference became highly significant at 6 years, with a substantially higher PFS rate being observed for patients on BTKi maintenance therapy (91.3% [95% CI: 69.5–97.7%]) than for those on lenalidomide maintenance therapy (41.5% [95% CI: 23.8–58.4%]) ( P < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.